BofA analyst Koji Ikeda is moving to No Rating on Enfusion (ENFN) after it was announced that the investment management vertical software vendor is being acquired by Clearwater Analytics (CWAN) for $1.5B in a mix of cash and stock. Given Enfusion’s current growth and profitability profile, the firm believes the acquisition price is “reasonable,” adding that it believes shares are no longer trading on fundamentals due to the proposed acquisition.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENFN:
- Clearwater-Enfusion merger makes sense strategically, says Oppenheimer
- Enfusion downgraded to Market Perform from Outperform at William Blair
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Enfusion downgraded to Hold from Buy at Stifel
- Enfusion to Merge with Clearwater Analytics Holdings